Cargando…
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism. Polymorphisms resulting in decreased enzyme activity are common in the CYP2C9 gene and this, combined with narrow therapeutic indices for several key drug subs...
Autores principales: | Daly, Ann K., Rettie, Allan E., Fowler, Douglas M., Miners, John O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872075/ https://www.ncbi.nlm.nih.gov/pubmed/29283396 http://dx.doi.org/10.3390/jpm8010001 |
Ejemplares similares
-
Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
por: Agrawal, Saaket, et al.
Publicado: (2020) -
Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020) -
Pharmacogenomics of adverse drug reactions
por: Daly, Ann K
Publicado: (2013) -
Landmarks of pharmacogenomics and some considerations for clinical practice
por: Ampong, David Nana
Publicado: (2019) -
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)